Decision Support Systems and Closed-Loop

Dovc K , Battelino T . Evolution of diabetes technology. Endocrinol Metab Clin North Am, 2020; 49: 1–18.

Nimri R . Decision support systems for insulin treatment adjustment in people with type 1 diabetes. Pediatr Endocrinol Rev, 2020; 17: 170–182.

Tyler NS , Mosquera-Lopez CM , Wilson LM , et al. An artificial intelligence decision support system for the management of type 1 diabetes. Nat Metab, 2020; 2: 612–619.

Breton MD , Kanapka LG , Beck RW , et al., for the iDCL Trial Research Group. A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes. N Engl J Med, 2020; 383: 836–845. PMID: 32846062.

Bode BW. Safety and glycemic outcomes of the MiniMed advanced hybrid closed-loop (AHCL) system in subjects with T1D. 80th Virtual Scientific Sessions of the American Diabetes Association, June 2020.

Bergenstal RM. FLAIR—An NIDDK-sponsored international, multi-site randomized crossover trial of AHCL vs. 670G. 80th Virtual Scientific Sessions of the American Diabetes Association, June 2020.

Buckingham BA. Omnipod^® 5 automated glucose control system, powered by Horizon™: first outpatient study results. 80th Virtual Scientific Sessions of the American Diabetes Association, June 2020.

Brown SA , Buckingham B , Kudva YC , et al., for the IDCL Trial Group. 18-Month use of closed-loop control (CLC): a randomized, controlled trial. 80th Virtual Scientific Sessions of the American Diabetes Association, June 2020.

Buckingham BA , Forlenza GP , Pinsker JE , et al. Safety and feasibility of the Omnipod hybrid closed-loop system in adult, adolescent, and pediatric patients with type 1 diabetes using a personalized model predictive control algorithm. Diabetes Technol Ther, 2018; 20: 257–262.

Buckingham BA , Christiansen MP , Forlenza GP , et al. Performance of the Omnipod personalized model predictive control algorithm with meal bolus challenges in adults with type 1 diabetes. Diabetes Technol Ther, 2018; 20: 585–595.

Forlenza GP , Buckingham BA , Christiansen MP , et al. Performance of Omnipod personalized model predictive control algorithm with moderate intensity exercise in adults with type 1 diabetes. Diabetes Technol Ther, 2019; 21: 265–272.

Castle JR , El Youssef J , Wilson LM , et al. Randomized outpatient trial of single- and dual-hormone closed-loop systems that adapt to exercise using wearable sensors. Diabetes Care, 2018; 41: 1471–1477.

Haidar A , Legault L , Matteau-Pelletier L , et al. Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial. Lancet Diabetes Endocrinol, 2015; 3: 595–604.

Evans M , Ceriello A , Danne T , et al. Use of fast-acting insulin aspart in insulin pump therapy in clinical practice. Diabetes Obes Metab, 2019; 21: 2039–2047.

Hsu LJ , Buckingham BA , Basina M , et al. Fast-acting insulin aspart use with the MiniMed™ 670G system. Diabetes Technol Ther 2020 Jun 10. DOI: 10.1089/dia.2020.0083 [Epub ahead of print].

Bally L , Herzig D , Ruan Y , et al. Short-term fully closed-loop insulin delivery using faster insulin aspart compared with standard insulin aspart in type 2 diabetes. Diabetes Obes Metab, 2019; 21: 2718–2722.